31 studies found for:    Guillain-Barré Syndrome
Show Display Options
Rank Status Study
21 Unknown  Perception and Multisensory Integration in Neurological Patients Using fMRI
Conditions: Acute Inflammatory Demyelinating Polyradiculoneuropathy;   Myasthenia Gravis;   Stroke;   Anosognosia;   Asomatognosia
Intervention: Device: Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
22 Completed Cervarix Long-term Safety Surveillance
Condition: Infections, Papillomavirus
Interventions: Biological: Cervarix;   Other: Data collection
23 Completed Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
Condition: Observation Safety
Intervention:
24 Completed Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801
Condition: Prophylaxis of Ross River Virus Infection
Intervention: Biological: Ross River Virus (RRV) Vaccine
25 Unknown  Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.
Condition: Spinal Cord Injury
Intervention:
26 Completed
Has Results
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
Condition: Novel Influenza A/H1N1
Intervention:
27 Completed
Has Results
Surveillance for Adverse Events Following Influenza Immunization
Conditions: Influenza;   Vaccines Adverse Reaction
Intervention:
28 Recruiting Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients
Condition: Eating Disorders
Intervention:
29 Completed Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
Condition: Autoimmune Diseases in Subjects Receiving Cervarix®
Intervention: Other: Data collection
30 Active, not recruiting Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
Condition: Infections, Meningococcal
Intervention: Biological: Nimenrix™
31 Active, not recruiting Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal vaccine GSK134612

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-31) Next Page   
Indicates status has not been verified in more than two years